Drugs / MLC1501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04233437 | Feb → May 2020 | stroke disorder | Moleac Pte Ltd. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT05289947 Comparator | Jul 2023 → Jul 2025 | ischemic stroke, thrombotic disease | Moleac Pte Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT05046106 Comparator | Jan 2025 → Sep 2028 expected | intracranial embolism, thrombotic disease | Moleac Pte Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-03-08 | Moleac Pte Ltd. | Regulatory Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery moleac.com ↗
Moleac, a biopharmaceutical company based in Singapore, announced the approval by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for MLC1501 in traumatic brain injury (TBI). |
| 2022-03-08 | Moleac Pte Ltd. | Regulatory Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Stroke Recovery moleac.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for a Phase 1 study of MLC1501, as first step of a clinical programme in post-stroke recovery treatment. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-03-08 | Moleac Pte Ltd. | Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery moleac.com ↗ |
| 2022-03-08 | Moleac Pte Ltd. | Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Stroke Recovery moleac.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MLC1501 | “MLC1501, consisting of four herbs, that is, Radix Astragali, Radix Angelicae sinensis, Rhizoma Chuanxiong, Radix Polygalae” PMID 39915229 ↗ Oct 2025 |
| Modality | Traditional medicine (herbal / TCM) | “Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala” NCT05046106 ↗ |
| Route | Oral | “orally receive MLC1501” NCT05046106 ↗ |